For US Healthcare Professionals

I am a

DOSING OPTIONS

The only IL-23i approved for SC dosing
from the start1*

With as little as 1 prior authorization to start and stay on therapy†

*"Only" based on approved selective IL-23 inhibitors for moderately to severely active Crohn’s disease as of March 2025. Compared to Skyrizi® (risankizumab-rzaa) and Omvoh® (mirikizumab-mrkz) induction and maintenance dosing. Skyrizi® and Omvoh® are not available as SC injection for induction therapy in Crohn’s disease.1-3

†Individual patient coverage may vary.

Tremfya Pen
Tremfya Pen

INDUCTION DOSING1

Tremfya PEN
Not actual size.

INDUCTION—SC

3 SC TREMFYA® PEN
Induction Packs1‡

400-mg SC injection (given as two consecutive injections of 200 mg each) at Weeks 0, 4, and 8

TREMFYA® is also available in 200-mg prefilled syringes

OR

TREMFYA® is also available in 200-mg prefilled syringes

OR

Indication IV
Indication IV
Not actual size.

INDUCTION—IV

IV infusion (200 mg)§

3 IV induction doses

200-mg IV infusion at Weeks 0, 4, and 8

200-mg IV infusion administered over at least 1 hour

200-mg IV infusion administered over at least 1 hour

‡Induction Pack for Crohn’s disease: Outer carton containing two inner cartons, each containing one 200 mg/2 mL single-dose prefilled pen (TREMFYA® PEN).1

§200 mg/20 mL (10 mg/mL) solution in a single-dose vial.1

MAINTENANCE DOSING1

Not actual size.

TREMFYA® PEN (200 mg)*

200 mg administered by SC injection at
Week 12, and every 4 weeks thereafter

Also available in prefilled syringe (200 mg/2 mL)

Also available in prefilled syringe (200 mg/2 mL)

OR

Not actual size.

TREMFYA® PEN (100 mg)†

100 mg administered by SC injection at Week 16, and every 8 weeks thereafter

Also available in One-Press patient-controlled
injector or prefilled syringe (100 mg/mL)

Also available in One-Press patient-controlled injector or prefilled syringe (100 mg/mL)

Use the lowest effective recommended dosage to maintain therapeutic response.

*200 mg/2 mL in a single-dose prefilled pen.1

†100 mg/mL in a single-dose prefilled pen.1

Pretreatment Evaluations: Evaluate for tuberculosis (TB) infection, obtain liver enzymes and bilirubin levels, and complete all age-appropriate vaccinations according to current immunization guidelines.1

Monitor: For signs and symptoms of active TB during and after treatment with TREMFYA®; liver enzymes and bilirubin levels for at least 16 weeks of treatment, and periodically thereafter according to routine patient management.1

TREMFYA® is intended for use under the guidance and supervision of a healthcare professional. TREMFYA® may be administered by a healthcare professional, or a patient/caregiver may inject after proper training in subcutaneous injection technique.1

IL-23i=interleukin-23 inhibitor; IV=intravenous.

DEVICES

TREMFYA® is available with three different subcutaneous devices for your patients1

200 mg/2 mL1

TREMFYA® PEN

Not actual size.

TREMFYA® PEN

TREMFYA® comes in a single-dose prefilled pen containing one 200-mg dose. Each TREMFYA® PEN is for one-time use only.

OR

Prefilled syringe

Not actual size.

Prefilled syringe

TREMFYA® comes in a single-dose prefilled syringe containing one 200-mg dose. Each TREMFYA® prefilled syringe is for one-time use only.

100 mg/mL1

TREMFYA® PEN

Not actual size.

TREMFYA® PEN

TREMFYA® comes in a single-dose prefilled pen containing one 100-mg dose. Each TREMFYA® PEN is for one-time use only.

OR

One-Press

Not actual size.

One-Press

TREMFYA® comes in a single-dose One-Press patient-controlled injection containing one 100-mg dose. Each One-Press injector is for one-time use only.

OR

Prefilled syringe

Not actual size.

Prefilled syringe

TREMFYA® comes in a single-dose prefilled syringe containing one 100-mg dose. Each TREMFYA® prefilled syringe is for one-time use only.

Once you have determined the appropriate dose for your patient, you and your patient can choose which device may be best suited for them.1

Please see the full Instructions for Use for the TREMFYA® PEN, One-Press patient-controlled injector, and prefilled syringe.

PRESCRIBING TREMFYA®

Write 2 prescriptions for TREMFYA®1

Write 1 prescription for induction dosing and 1 prescription for maintenance dosing 

RX #1

SC Induction Dosing

Write one Rx for TREMFYA® Crohn’s disease SC Induction (400 mg SC q4w).*†

The recommended induction dosage of TREMFYA® is 400 mg administered by subcutaneous injection (given as two consecutive injections of 200 mg each) at Week 0, Week 4, and Week 8.

*200 mg/2 mL in a single-dose prefilled pen.

† 200 mg/2 mL or 100 mg/mL in a single-dose prefilled syringe.

‡ 2 200 mg/mL (10 mg/mL) solution in a single-dose vial. 

OR

IV induction dosing

Write one Rx for TREMFYA® Crohn’s disease IV Induction (200 mg IV q4w).‡

The recommended induction dosage of TREMFYA® is 200 mg administered by intravenous infusion over at least 1 hour at Week 0, Week 4, and Week 8.

Write one Rx for TREMFYA® Crohn’s disease SC Induction (400 mg SC q4w).*†

The recommended induction dosage of TREMFYA® is 400 mg administered by subcutaneous injection (given as two consecutive injections of 200 mg each) at Week 0, Week 4, and Week 8.

Write one Rx for TREMFYA® Crohn’s disease IV Induction (200 mg IV q4w).‡

The recommended induction dosage of TREMFYA® is 200 mg administered by intravenous infusion over at least 1 hour at Week 0, Week 4, and Week 8.

*200 mg/2 mL in a single-dose prefilled pen.

†200 mg/2 mL in a single-dose prefilled syringe.

‡200 mg/mL (10 mg/mL) solution in a single-dose vial. 

RX #2

SC MAINTENANCE DOSING

OR

Write one Rx for TREMFYA® Crohn’s disease SC maintenance (200 mg§|| q4w or 100 mg§||¶ q8w).

The recommended maintenance dosage of TREMFYA® is:

100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter§||¶

OR

200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter§||

Use the lowest effective recommended dosage to maintain therapeutic response.

Please refer to the full Prescribing Information for the complete dosing information.

Pretreatment Evaluations: Evaluate for tuberculosis (TB) infection, obtain liver enzymes and bilirubin levels, and complete all age-appropriate vaccinations according to current immunization guidelines.1

Monitor: For signs and symptoms of active TB during and after treatment with TREMFYA®; liver enzymes and bilirubin levels for at least 16 weeks of treatment, and periodically thereafter according to routine patient management.1

TREMFYA® is intended for use under the guidance and supervision of a healthcare professional. TREMFYA® may be administered by a healthcare professional, or a patient/caregiver may inject after proper training in subcutaneous injection technique.1

§200 mg/2 mL or 100 mg/mL in a single-dose prefilled pen.1

||200 mg/2 mL or 100 mg/mL in a single-dose prefilled syringe.1

100 mg/mL in a single-dose One-Press patient-controlled injector.1

IV=intravenous; q4w=every 4 weeks; q8w=every 8 weeks; SC=subcutaneous; SUBQ=subcutaneous. 

These videos are not meant to replace the Instructions for Use (IFU) that are supplied with TREMFYA®. Instruct patients to read the IFU before using their TREMFYA® PEN, TREMFYA® prefilled syringe, or One-Press patient-controlled injector and each time they get a refill. Please see the full IFU for TREMFYA®.

TREMFYA® PEN Demonstration

Video Play

TREMFYA® Prefilled Syringe Demonstration

Video Play

TREMFYA® One-Press Demonstration

Video Play

TREMFYA® is intended for use under the guidance and supervision of a healthcare professional. TREMFYA® may be administered by a healthcare professional, or a patient/caregiver may inject after proper training in subcutaneous injection technique.1

teal vector
teal vector
global

Schedule a meeting with a local representative of Johnson & Johnson

Request a rep

Explore TREMFYA® Efficacy

Banner Image

References: 1. TREMFYA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Skyrizi® [Prescribing Information]. North Chicago, IL: AbbVie Inc. 3. Omvoh® [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company.